FDA Drug Recalls

11,815 recalls · Class II, newest first

Class II · Moderate risk Terminated Jun 2, 2015

Bi-Mix

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1665-2015

Class II · Moderate risk Terminated Jun 2, 2015

Bi-Mix #1

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1664-2015

Class II · Moderate risk Terminated Jun 2, 2015

Zinc Chloride 25mg/ml Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1663-2015

Class II · Moderate risk Terminated Jun 2, 2015

Zinc 5 mg/ml Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1662-2015

Class II · Moderate risk Terminated Jun 2, 2015

Vancomycin 25 mg/ml Ophthalmic Solution

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1661-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone 75 mg and B12 6 mg Pellet

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1660-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone 200 mg Anastrazole 9 mg Pellet

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1659-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone 200 mg Anastrazole 1 mg Pellet

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1658-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone 60 mg Anastrazole 4 mg Pellet

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1657-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone 80 mg Pellet

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1656-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone 75 mg Pellet

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1655-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone 72.5 mg Pellet

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1654-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone 70 mg Pellet

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1653-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone 62.5 mg Pellet

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1652-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone 50 mg Pellet

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1651-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone USP

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1650-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone Propionate 100 mg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1649-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone USP Aqueous 200 mg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1648-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone Enanthate 200 mg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1647-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone Cypionate 200 mg/ml Anastrazole 0.25 mg/ml Cholecalciferol 50

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1646-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone Cypionate 200 mg/ml Anastrazole 2 mg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1645-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone Cypionate 200 mg/ml Anastrazole 0.5 mg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1644-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone Cypionate 200 mg/ml Anastrazole 0.25 mg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1643-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone Cypionate 200mg/ml Injection Multi-Dose Vial

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1642-2015

Class II · Moderate risk Terminated Jun 2, 2015

Testosterone Cypionate 150 mg/ml Injection Multi-Dose Vial

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1641-2015